

## Sobrera Pharma receives patent approval in Europe



**Sobrera Pharma AB is pleased to announce the Decisions to Grant on the European patent 3582764 titled 'Treatment of Alcohol Use' by the European Patent Office (EPO). The decision to grant on the patent provides a protection of our drug candidate SO-001 for use in treating alcohol use disorder (AUD) and/or treating alcohol risk consumption.**

The invention is based on research at the Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy, University of Gothenburg led by Prof. Bo Söderpalm and Dr. Andrea de Bejczy

"We are delighted that this European patent has been granted, strengthening Sobrera's intellectual property portfolio for SO-001 in treatment of alcohol addiction Ann-Charlotte Rosendahl, CEO.

Sobrera focuses on research and development of new treatments within psychiatry with an initial focus on addiction disorders. The product SO-001 constitutes a new concept in treating AUD, directing its effect on the dopamine system, which plays an important role in the reward system and in addictive disorders. Preclinical data has shown promising results and a phase II study is now ongoing to evaluate the efficacy and safety of the new therapy in patients with AUD.

Alcohol addiction is a common and serious health issue globally, and a major cause of mortality and morbidity. New and improved therapies are needed to help better manage this condition.

**For more information, please contact**

Ann-Charlotte Rosendahl  
+46 73 2096405  
[ann-charlotte.rosendahl@sobrera.com](mailto:ann-charlotte.rosendahl@sobrera.com)

**About Sobrera Pharma**

*Sobrera Pharma AB is a clinical stage pharmaceutical company developing new treatments for patients with substance use disorders. The company's initial focus is the product SO-001. A phase II development is ongoing in patients with moderate to severe Alcohol Use Disorder. Alcohol addiction is a major global health issue and a major cause of mortality and morbidity. Sobrera's vision is to offer an effective and easy to use treatment to improve health and quality of life, to reduce the risk of morbidity and premature death in patients with substance use disorders, and to reduce the related societal costs. The company is headquartered in Gothenburg, Sweden.*

More information at [www.sobrera.com](http://www.sobrera.com)